Department of Pharmacology and Clinical Neuroscience, Section of Neurology at Umeå University, Sweden.
Mult Scler. 2013 Jul;19(8):1022-7. doi: 10.1177/1352458512470862. Epub 2012 Dec 20.
Smoking has been associated with an increased risk for multiple sclerosis, but no studies have measured levels of the nicotine metabolite cotinine in prospectively collected samples to assess exposure.
To investigate the effects of laboratory defined tobacco use on the risk for multiple sclerosis using prospectively collected biobank blood samples.
Levels of cotinine were measured in n=192 cases, and n=384 matched controls, using an immunoassay. The risk for multiple sclerosis was estimated using matched logistic regression.
Elevated cotinine levels (≥10 ng/ml) were associated with a significantly increased risk for multiple sclerosis, (odds ratio, OR 1.5, 95% confidence interval, CI 1.0-2.1). This association was only present in young individuals (below median age at blood sampling, <26.4 years), (OR 2.2, 95% CI 1.3-3.8).
This study confirms that smoking is a risk factor for multiple sclerosis. It has the advantage of using analyses of cotinine levels in samples that were collected several years before disease onset, thus excluding any risk for recall bias and minimising the risk for reversed causation. Our results also suggest that the smoking related immunological events that contribute to the development of multiple sclerosis occur early in life.
吸烟与多发性硬化症的风险增加有关,但尚无研究测量前瞻性收集的样本中尼古丁代谢物可替宁的水平,以评估暴露情况。
使用前瞻性收集的生物银行血液样本,研究实验室定义的烟草使用对多发性硬化症风险的影响。
使用免疫测定法测量 n=192 例病例和 n=384 例匹配对照者的可替宁水平。使用匹配的逻辑回归估计多发性硬化症的风险。
可替宁水平升高(≥10ng/ml)与多发性硬化症的风险显著增加相关(比值比,OR 1.5,95%置信区间,CI 1.0-2.1)。这种关联仅存在于年轻人中(血液样本采集时年龄低于中位数,<26.4 岁)(OR 2.2,95%CI 1.3-3.8)。
这项研究证实吸烟是多发性硬化症的一个危险因素。它的优势在于使用在疾病发作前几年采集的样本中可替宁水平的分析,从而排除了任何回忆偏倚的风险,并最大程度地降低了反向因果关系的风险。我们的结果还表明,导致多发性硬化症发生的与吸烟有关的免疫事件发生在生命早期。